Early Results: “ROCKET” a phase II study of RRx-001, a novel triple epigenetic inhibitor. Resensitization to irinotecan in colorectal cancer

Date 02 March 2015
Event 13th International Congress on Targeted Anticancer Therapies
Session Phase 1 studies: Miscellaneous drugs & targets
Topics Anticancer Agents
Clinical Research
Colon and Rectal Cancer
Basic Scientific Principles
Biological Therapy
Presenter Corey Carter